

PATENT Attorney Docket No. WYE-076

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):

Aston et al.

CONFIRMATION NO.:

8289

SERIAL NO.:

10/706,791

GROUP NO.:

1634

FILING DATE:

November 12, 2003

EXAMINER:

Lu, Frank Wei Min

TITLE:

Methods and Compositions for Treating Neurological Disorders

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:


In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the non-U.S. patent documents and non-patent publications are enclosed.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

	(1)	within three (3) months of the filing date of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. 1.491 in an
		international application, or before the mailing of the first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. 1.114; or
\boxtimes	(2)	after the period defined in (1) above but before the mailing date of any of a final action under 37 C.F.R. 1.113, a notice of allowance under 37 C.F.R. 1.311, or an action that otherwise closes prosecution in the application, and
		the requisite Statement is below, OR
	\boxtimes	the requisite fee under 37 C.F.R. 1.17(p), namely \$180.00, is included herein; or
09/19/2006 WASFAW1	00000080 107	06791
02 FC:1806		180.00 OP

	Supplemental In Serial No.: 10/7 Page 2 of 2		ation Disclosure Statement							
		3) after the period defined in (2) above but before the payment of the issue								
	[the requisite Statement is below, AND							
the requisite petition fee under 37 C.F.R. 1.17(p), namely \$180.00 is included										
It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.										
				Respectfully submitted,						
	Date: Septer Reg. No. 48,0 Tel. No.: (61 Fax No.: (61	6450 7) 26	51-3169	Brian A. Fairchild Attorney for Applicants Kirkpatrick & Lockhart Nicholson Graham LLP State Street Financial Center One Lincoln Street Boston, Massachusetts 02111-2950						
	BOS-1007046 v1									





SHEET 1 OF 1

الرابال														
FORM PTO - 1449					ATTORNEY DOCKET NO.: WYE-076									
SUPPLEMENTAL					AP	PLICANT	Γ(S):			Aston et al.				
INFORM	MATIO	N DISCLOSUI	RE STATEME	ENT	SE	RIAL NO	.:			10/70	10/706,791			
					FILING DATE:					November 12, 2003				
					GROUP NO.:					1634				
			U.S	S. PATEN	T D	OCUME	NTS					"		
EXAM.										SUB		FILING DATE IF		
INIT.		NUMBER	DATE	NAME				CLASS		CLASS		APPROPRIATE		
				<u> </u>										
							_	_						
==														
	_				_									
			FORE	IGN PAT	ΓEN	T DOCU	MENT	S.		l		L.		
EXAM. INIT.		DOCUMENT NÚMBER	DATE	COUNT	RY CLASS		SUB CLAS	FILIT S DATI		1		BSTRACT NLY	ENGLISH LANG (Y/N)	
	<u>'</u>		OTHER A	RT, JOU	RN	AL ARTI	CLES,	ET.	rc.					
EXAM. INIT.	ОТНЕ	R DOCUMENTS:	(Including Autho	r, Title, Dat	e, Re	elevant Page	s, Place	of P	ublicati	on)				
	C1	C1 Mackay et al., "Neuroprotective Effects of Insulin-Like Growth Factor-Binding Protein Ligand Inhibitors in Vitro and in Vivo," J. Cereb. Blood Flow Metab., 23(10):1160-1167 (2003).												
	C2													
EXAMINER				DATE CONSIDERED										